Clinical Trial Search

Primary: Change From Baseline to Week 12 in Seated Diastolic Blood Pressure (SeDBP). — -17.8; -16.5; -14.8; -21.5 mm Hg — p=<0.0001

Primary: Number of Subjects With Anti-Hepatitis B Surface Antigen (Anti-HBs) Antibody Concentrations Above the Cut-off Value for Seroprotection — 190; 181 Participants

Primary: Change From Baseline in Annual Growth Rate Measured at 2 Years Following Treatment With Genotonorm — 3.07; 3.97; 2.84 cm/year — p=0.02922

Primary: Rate of Change on the ADAS-Cog 11. — 7.98; 8.27 ADAS points per year

Primary: Prolonged Smokeless Tobacco Abstinence at 3 Months — 65; 41 Participants — p=<0.05

Primary: Anti-hepatitis A Virus (Anti-HAV) Antibody Concentration — 369.1; 323.5; 293.7; 298.2 mIU/mL

Primary: Anti-hepatitis A Virus (Anti-HAV) Antibody Concentration — 692.3; 753.6; 544.4; 479.5 milli-international units per milliliter

Primary: Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Neutralizing Antibodies — 36791.8; 10053.1; 16486.9; 2257.9 titer

Primary: Change From Baseline in Brief Psychiatric Rating Scale (BPRS) Total Scores at 72 Hours — -17.32; -18.44 scores on a scale

Primary: Difference Between the Anakinra Arm and Placebo Arm in Change in End-systolic Volume Indices From Baseline to Follow up Exam 10-14 Weeks Later at Cardiac Magnetic…

Primary: Number of Patients From Group B Who Achieve a Physician's Global Assessment (PGA) of Clear or Almost Clear at Week 12. — 11 Participants

Primary: Overall Survival — 8.5; 9.2 Months

Primary: Time to Start of Relief of Symptoms From HAE Attack — 1.17; 0.5; 1.5 Hours — p=0.0025

Primary: Change in Glycosylated Hemoglobin (HbA1c) — -1.00; -1.14 Percentage of glycosylated hemoglobin — p=0.055

Primary: Change From Baseline in Percentage of Lesion Count — -43.3; -77.4 percentage of lesion count